

INTERRUPTION AND DISCONTINUATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN PSITAR HIV COHORT

Robustillo-Cortés MA¹, Jiménez-Galan R¹, Gómez-Fernández E¹, Trisancho-Pérez A¹, Manzano-García M¹, Calvo-Cidoncha E¹, Alvaro-Sanz E², Rios-Sanchez E³, Tortajada-Goitia B², Morillo-Verdugo R¹.

¹Valme University Hospital, Pharmacy, Seville, Spain. ²Costa del Sol Hospital, Pharmacy, Marbella, Spain.

³Puerto Real Hospital, Pharmacy, Puerto Real, Spain

BACKGROUND


Treatment modifications within the first year were extremely important. The first Highly active antiretroviral therapy (HAART) regimen should remain years. First regimen toxicity can have a negative impact on adherence and virologic efficacy

OBJECTIVES

To establish the main reason for discontinuing antiretroviral treatment within the first year in a HIV cohort.

STUDY DESIGN

- Design: Prospective multicenter study
- Population: Naive adult HIV patients who started treatment between 2011 and 2013.
- Demographic variables: Sex and age.
- Pharmacotherapeutic variables: Initial HAART, discontinuation of HAART within the first year and its reasons based on Swiss HIV Cohort (Elzi et al. Arch Intern Med. 2010)




Start HAART in Psitar cohort patients


RESULTS

277 patients started HAART between 2011 and 2013, 82,4% men. The mean age was 40 ± 11

Causes for discontinuing antiretroviral treatment within the first year in psitar hiv cohort (n=68)



Drug Toxicity (n patients)



CONCLUSIONS

The number of patients with discontinuation of HAART in the first year is acceptable. It is necessary to properly assess starting HAART to reduce adverse reactions involving switching the treatment